Extremely low excretion of daptomycin into breast milk of a nursing mother with Methicillin-Resistant Staphylococcus aureus pelvic inflammatory disease

Pharmacotherapy

Volumn 29, Issue 3, 2009, Pages 347-351

  Buitrago, Martha I ^a   Crompton, Jason A ^b   Bertolami, Shellie ^b   North, Donald S ^b   Nathan, Richard A ^a  

^a PLLC   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Breastfeeding; Daptomycin; Infectious disease; Methicillin resistant Staphylococcus aureus; MRSA; Pelvic inflammatory disease; Pharmacokinetics; PID

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CHLORHEXIDINE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; PSEUDOMONIC ACID; TETRACYCLINE; VANCOMYCIN;

ADD ON THERAPY; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BREAST FEEDING; BREAST MILK; CASE REPORT; DEVICE REMOVAL; DRUG EXCRETION; DRUG EXPOSURE; DRUG MILK LEVEL; ENDOMETRIUM BIOPSY; FEMALE; FEVER; FOLLOW UP; HOT FLUSH; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PELVIC INFLAMMATORY DISEASE; PRENATAL DEVELOPMENT; RISK ASSESSMENT; STAPHYLOCOCCUS INFECTION; URINARY TRACT INFECTION; UTERUS PERFORATION; VAGINA DISCHARGE; VAGINITIS; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; BREAST FEEDING; DAPTOMYCIN; FEMALE; HUMANS; INFANT; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MILK, HUMAN; PELVIC INFLAMMATORY DISEASE; STAPHYLOCOCCAL INFECTIONS;

EID: 62549111683     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.3.347     Document Type: Article

References (25)

1. Meirik O. Intrauterine devices: upper and lower genital tract infections. Contraception 2007;75(6 suppl):S41-7.
2. Grodstein F, Rothman KJ. Epidemiology of pelvic inflammatory disease. Epidemiology 1994;5(2):234-42.
3. Walker CK, Wiesenfeld HC. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2007;44(suppl 3):S111-22.
4. Reali A, Ximenes A, Cuzzolin L, Fanos V. Antibiotic therapy in pregnancy and lactation. J Chemother 2005;17(2):123-30.
5. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38(12):1673-81.
6. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355(7):653-65.
7. Cubist Pharmaceuticals, Inc. Internal report 2007-0420. Data on file. Lexington, MA; 2007.
8. Sutton MY, Sternberg M, Zaidi A, St Louis ME, Markowitz LE. Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985-2001. Sex Transm Dis 2005;32(12):778-84.
9. Dunbar-Jacob J, Sereika SM, Foley SM, Bass DC, Ness RB. Adherence to oral therapies in pelvic inflammatory disease. J Womens Health (Larchmt) 2004;13(3):285-91.
10. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the pelvic inflammatory disease evaluation and clinical health (PEACH) randomized trial. Am J Obstet Gynecol 2002;186(5):929-37.
11. Faro S, Martens M, Maccato M, Hammill H, Pearlman M. Vaginal flora and pelvic inflammatory disease. Am J Obstet Gynecol 1993;169(2 pt 2):470-4.
12. Association for Professionals in Infection Control and Epidemiology, Inc. National prevalence study of methicillin-resistant Staphylococcus aureus (MRSA) in U.S. healthcare facilities: executive summary. June 25, 2007. Available from www.apic.org/content/NavigationMenu/ResearchFoundation/ previousstudies/nationalMRSAprevalencestudy/APIC-MRSA-STUDY-EXEC.pdf. Accessed July 16, 2007.
13. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin- resistant Staphylococcus aureus infections in the United States. JAMA 2007;298(15):1763-71.
14. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42(6):2398-402.
15. C ubist Pharmaceuticals, Inc. Cubicin (daptomycin for injection) full prescribing information. Lexington, MA; 2006. Available from www.cubicin.com/2006-full-pi.pdf. Accessed July 16, 2007.
16. Gartner LM, Morton J, Lawrence RA, et al. Breastfeeding and the use of human milk. Pediatrics 2005;115(2):496-506.
17. Committee on Health Care for Underserved Women, American College of Obstetricians and Gynecologists. ACOG committee opinion no. 361: breastfeeding-maternal and infant aspects. Obstet Gynecol 2007;109(2 pt 1):479-80.
18. James DC, Dobson B. Position of the American Dietetic Association: promoting and supporting breastfeeding. J Am Diet Assoc 2005;105(5):810-18.
19. Moreland J, Coombs J. Promoting and supporting breastfeeding. Am Fam Physician 2000;61(7):2093-100, 2103-4.
20. U.S. Department of Health and Human Services, Office on Women's Health. HHS blueprint for action on breastfeeding. Washington, DC: U.S. Department of Health and Human Services, 2000.
21. Ito S, Lee A. Drug excretion into breast milk: overview. Adv Drug Deliv Rev 2003;55(5):617-27.
22. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 1 2 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50(10):3245-9.
23. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47(4):1318-23.
24. Cubist Pharmaceuticals, Inc. Cubicin pH and osmolality following reconstitution. Data on file. Lexington, MA; 2008.
25. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38(7):994-1000.